AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO €18,000,000 Dated 27th August 2019 BetweenAgreement • September 4th, 2020 • Orphazyme a/S • Pharmaceutical preparations • England
KREOS CAPITAL VI (UK) LIMITED, a company incorporated in England and Wales under registration number 11535385 whose registered office is at Amf Building, 25 Old Burlington Street, London W1S 3AN (the “Lender”, which expression shall include its successors and assigns);
ASSET PURCHASE AGREEMENT by and between CytRx Corporation, as Seller, and Orphazyme ApS, as Buyer May 13, 2011Asset Purchase Agreement • September 4th, 2020 • Orphazyme a/S • Pharmaceutical preparations
This Asset Purchase Agreement (this “Agreement”) is made as of May 13, 2011, by and between CytRx Corporation, a Delaware corporation (“Seller”), and Orphazyme ApS, a company organized under the laws of Denmark (“Buyer”). Seller and Buyer are each referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT dated October 31 2017 between Orphazyme A/S and KU Center for Technology Commercialization, Inc. and University of Kansas and Kansas Life Sciences Development Company, Inc. and UCL Business PLCLicense Agreement • September 4th, 2020 • Orphazyme a/S • Pharmaceutical preparations
This License Agreement (“Agreement”) is entered into as of October 31, 2017 by and among the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC. d/b/a KU Innovation and Collaboration, having its principal place of business at 2029 Becker Drive, Suite 142, Lawrence, KS 66047, hereinafter referred to as “KUCTC,” UNIVERSITY OF KANSAS, on behalf of University of Kansas Medical Center, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KUMC,” KANSAS LIFE SCIENCES DEVELOPMENT COMPANY, INC., having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KLSDC,” and collectively, with KUCTC and KUMC, “Kansas,” UCL BUSINESS PLC, having its principal place of business at 97 Tottenham Court Road, London W1T 4TP, UK, hereinafter referred to as “UCLB,” and ORPHAZYME A/S, having its principal place of business at Ole Maaløes Vej 3, DK-2200 N, Copenhagen, Denmark, hereinafter r
UNIVERSITY OF MIAMI EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 4th, 2020 • Orphazyme a/S • Pharmaceutical preparations
This Exclusive License Agreement (this “Agreement”) is entered into and made effective as of the last dated signature below (the “Effective Date”) between University of Miami, a Florida not-for-profit corporation, having business offices at 1951 NW 7th Avenue, (C234), Miami, Florida 33136 (“UNIVERSITY”), on behalf of itself, Emory and MGH (as defined below), and Orphazyme ApS, CVR no. DK 3226 6355, a for-profit corporation organized under the laws of Denmark, having business offices at Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark (“LICENSEE”). For purposes of this Agreement, each of UNIVERSITY and LICENSEE may be individually referred to as a “Party” and collectively referred to as the “Parties.”
